Advertisement

Drugs & Aging

, Volume 23, Issue 12, pp 997–1001 | Cite as

Intravenous Ibandronate in the Treatment of Osteoporosis

Profile Report
  • Katherine F. Croom
  • Lesley J. Scott
Adis Profile Report
  • 22 Downloads

Osteoporosis is a progressive disease characterised by decreased bone mass and disordered bone architecture, leading to fragility and an increased risk of fractures, particularly of the spine, hip and wrist.[7] When described in terms of bone mineral density (BMD), osteoporosis is defined as BMD more than 2.5 standard deviations below the mean for young normal subjects of the same gender (T score < −2.5).[7] The risk of osteoporosis increases with age and, while it occurs in both men and women, it is especially common in postmenopausal women, related to a decrease in estrogen-mediated suppression of bone resorption.[7,8] At least one in three women over the age of 50 years will experience an osteoporotic fracture.[7,8]

The main aim of treatment is to reduce the risk of fractures, which can be achieved by slowing bone loss and improving bone mass and quality.[8] Lifestyle preventive measures include dietary considerations, exercise, avoidance of smoking and limiting alcohol intake.[8]...

Keywords

Bone Mineral Density Osteoporosis Bisphosphonates Alendronate Risedronate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Croom KF, Scott LJ. Intravenous ibandronate: in the treatment of osteoporosis. Drugs 2006; 66(12): 1593–601PubMedCrossRefGoogle Scholar
  2. 2.
    Reginster J-Y. Intravenous ibandronate in the treatment of osteoporosis: a viewpoint. Drugs 2006; 66(12): 1602–3CrossRefGoogle Scholar
  3. 3.
    Compston J. Intravenous ibandronate in the treatment of osteoporosis: a viewpoint. Drugs 2006; 66(12): 1602–3CrossRefGoogle Scholar
  4. 4.
    Adami S. Intravenous ibandronate in the treatment of osteoporosis: a viewpoint. Drugs 2006; 66(12): 1602–3CrossRefGoogle Scholar
  5. 5.
    Roche Products Limited. Bonviva 3mg/3ml solution for injection in pre-filled syringe: summary of product characteristics (EC) [online]. Available from URL: http://www.emc.medicines.org.uk [Accessed 2006 Apr 26]
  6. 6.
    Roche Laboratories Inc. Boniva® (ibandronate sodium) injection: package insert (US) [online]. Available from URL: http://www.rocheusa.com [Accessed 2006 Jul 25]
  7. 7.
    Scottish Intercollegiate Guidelines Network. Management of osteoporosis: a national clinical guideline. June 2003 (updated Apr 2004) [online]. Available from URL: http://www.sign.ac.uk [Accessed 2006 Jun 12]
  8. 8.
    The North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause 2006; 13(3): 340–67CrossRefGoogle Scholar
  9. 9.
    Cranney A. Treatment of postmenopausal osteoporosis: choice of treatment depends on efficacy, individual risk profile, and side effects. BMJ 2003; 327: 355–6PubMedCrossRefGoogle Scholar
  10. 10.
    Chapurlat RD. Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis. Treat Endocrinol 2005; 4(2): 115–25PubMedCrossRefGoogle Scholar
  11. 11.
    Chesnut CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19(8): 1241–9CrossRefGoogle Scholar
  12. 12.
    Roche Products Limited. Bonviva 150mg film-coated tablets: summary of product characteristics (EC) [online]. Available from URL: http://www.emc.medicines.org.uk [Accessed 2006 Jun 12]
  13. 13.
    Thiebaud D, Burckhardt P, Kriegbaum H, et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997 Oct; 103(4): 298–307PubMedCrossRefGoogle Scholar
  14. 14.
    Adami S, Felsenberg D, Christiansen C, et al. Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone 2004 May; 34(5): 881–9PubMedCrossRefGoogle Scholar
  15. 15.
    Recker R, Stakkestad JA, Chesnut CH, et al. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 2004 May; 34(5): 890–9PubMedCrossRefGoogle Scholar
  16. 16.
    Stakkestad JA, Benevolenskaya LI, Stepan JJ, et al. Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women. Ann Rheum Dis 2003 Oct; 62(10): 969–75PubMedCrossRefGoogle Scholar
  17. 17.
    Delmas PD, Adami S, Strugala CSJA, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis. Arthritis Rheum 2006; 54(6): 1838–46PubMedCrossRefGoogle Scholar
  18. 18.
    Emkey R, Zaidi M, Lewiecki EM, et al. Two-year efficacy and tolerability of intermittent intravenous ibandronate injections in postmenopausal osteoporosis: the DIVA study [abstract no. L8 plus poster]. 69th Annual Scientific Meeting of the American College of Rheumatology and the 40th Annual Meeting of the Association of Rheumatology Health Professionals: Late Breakers; 2005 Nov 12–17; San Diego (CA)Google Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  1. 1.Wolters Kluwer Health ¦ AdisMairangi Bay, AucklandNew Zealand
  2. 2.Editorial office of Wolters Kluwer HealthConshohockenUSA

Personalised recommendations